LIFE: Successfully completed first week of longevity trials

Bergen, Norway, 27 June 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can announce positive results from the first week of sensor longevity trials.

Reference is made to press release 18 June 2024 when the company initiated the trials with wireless readout. Already after the first week of the longevity trials, conducted at the Norwegian University of Life Sciences (NMBU), the reports show very positive results. The dog, Elli, is the first patient with the wireless glucose sensor. During the first seven days, the sensor implanted under Elli’s skin have transmitted far more than 1000 data points to an external reader.

– A week’s lifespan under the skin of a dog, in addition to the fact that such a large amount of data is read from the implanted sensor, is obviously a huge step for us in the right direction, says Managing Director Jo Amundstad of the subsidiary Lifecare Veterinary. He is responsible for the study in collaboration with NMBU.

– This is really a huge performance. We have been eager to start the longevity studies with wireless data-readout, being essential to confirm long-term sensor functionality in live tissue. Previously, the Sencell sensor has been implanted in clinical trials for up to three days in humans, with wired readout. It is groundbreaking for our technology when we note a functionality of more than a week in-vivo, and we are very proud of this achievement. The study is in its initial phase and this early result encourage us to expect a positive news flow from Jo and his team at NMBU as we proceed towards the veterinary market, says CEO Joacim Holter at Lifecare.

Elli is in good condition, and she has no complications after implementing the sensor. Hence the Lifecare-team at NMBU are stepping into the next phase of the longevity study. – We have placed a Freestyle Libre glucose monitor from Abbot on Elli’s skin. This will give us a reference source to our Sencell sensor under the dog’s skin and validate our monitored data. In addition, we will now prepare to enroll additional veterinary patients to expand the study in line with our protocol. We are really looking forward to the upcoming results of the longevity trials, says Jo Amundstad.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM“) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR“) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.